Sensitizer, kit and use for cancer therapy
AssigneeUropro Biotech Co., Ltd.
InventorPei-Ru Liao
Life of this patent
Estimating the term…
Abstract
A cancer therapy sensitizer is disclosed. The cancer therapy sensitizer includes rapamycin and substituted quinoline. The present invention discloses a cancer therapy sensitization kit containing the two aforementioned compounds and a use of a combination of the two aforementioned compounds as a cancer therapy sensitizer as well. The application of the cancer therapy sensitizer, the kit and the use of the present invention is advantageous for improving the treatment effect of cancer therapies.
Claims26
A cancer therapy sensitizer, comprising rapamycin and substituted quinoline, wherein the cancer therapy sensitizer applied in breast cancer, colon cancer and epidermoid carcinoma.
A cancer therapy sensitizer kit comprising:
- rapamycin and a first pharmaceutically acceptable carrier, diluent, excipient, or a combination thereof;
- and
- substituted quinoline and a second pharmaceutically acceptable carrier, diluent, excipient, or a combination thereof,
- wherein the cancer therapy sensitizer applied in breast cancer, colon cancer and epidermoid carcinoma.
A method of treating cancers, comprising:
- using a combination of a rapamycin and a substituted quinoline as a cancer therapy sensitizer, wherein the cancer therapy sensitizer applied in breast cancer, colon cancer and epidermoid carcinoma.
Dependencies are inferred from the claim text.